Last reviewed · How we verify
NCT03104335
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Phase 2 trial testing Apatinib in Soft Tissue Sarcoma Adult. Withdrawn.
30 June 2019
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 April 2017 |
| Primary completion | 30 June 2019 |
| Estimated completion | 1 March 2020 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Apatinib (Apatinib) — full drug profile →
Conditions studied
- Soft Tissue Sarcoma Adult — all drugs for Soft Tissue Sarcoma Adult →
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Peking University People's Hospital
Who can join
16 and older, any sex, with Soft Tissue Sarcoma Adult or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with advanced soft tissue sarcoma(rhabdomyosarcoma and liposarcoma excluded), who experience progression after standard chemotherapy, have limited treatment options which promise a survival benefit.This trial tends to explore apatinib, which is a domestic highly selective inhibitor of vascular endothelial growth factor receptor-2, as a treatment option for heavily pretreated soft tissue sarcoma patients.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Apatinib as targeted therapy for sarcoma.
Li F, Liao Z, Zhang C, Zhao J, et al · · 2018 · cited 16× · PMID 29849960 · DOI 10.18632/oncotarget.24647 -
Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
Elkrief A, Alcindor T. · · 2020 · cited 9× · PMID 32174756 · DOI 10.3747/co.27.5631 -
The changing landscape of phase II/III metastatic sarcoma clinical trials-analysis of ClinicalTrials.gov.
Que Y, Xiao W, Xu BS, Wen XZ, et al · · 2018 · cited 7× · PMID 30545340 · DOI 10.1186/s12885-018-5163-2
Verify or expand the search:
- PubMed search for NCT03104335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Apatinib
Trials testing the same drug.
- NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
- NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
- NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
- NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
- NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting
Other recruiting trials for Soft Tissue Sarcoma Adult
Currently open trials in the same condition.
- NCT07169344 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07173972 — Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. · Phase 2 · recruiting
- NCT05352750 — Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors · Phase 1 · active not recruiting
- NCT07432932 — Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients · recruiting
- NCT06385288 — Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas · NA · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03104335 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 19 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing